Can-Fite BioPharma

$2.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-7.26%) As of 9:05 AM EDT today
-$0.18 (-7.26%) Today

Why Robinhood?

You can buy or sell CANF and other stocks, options, ETFs, and crypto commission-free!

About CANF

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. Read More The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.

Employees
7
Headquarters
Petach Tikva, Tel Aviv
Founded
1994
Market Cap
7.61M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
43.06K
High Today
$2.29
Low Today
$2.28
Open Price
$2.28
Volume
5.63K
52 Week High
$25.95
52 Week Low
$2.15

Collections

CANF Earnings

-$0.09
-$0.05
-$0.01
$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.